ENDRA Life Sciences Inc. 8-K

What Happened
ENDRA Life Sciences, Inc. (NDRA) announced on June 25, 2026 via press release (filed on Form 8-K) a proposed merger of one of its subsidiaries with Noble Africa LLC. Noble Africa LLC is described as a wholly‑owned subsidiary of ASP Isotopes, Inc. and an intermediate holding company for Renergen Limited. The press release is included as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: June 25, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Transaction: Proposed merger of an ENDRA subsidiary with Noble Africa LLC (no financial terms or subordinate subsidiary name disclosed in the 8‑K).
• Counterparties: Noble Africa LLC is a wholly‑owned subsidiary of ASP Isotopes, Inc., and is the intermediate holding company for Renergen Limited.
• Disclosure: Press release furnished as Exhibit 99.1 (Item 9.01 lists exhibit).

Why It Matters
This 8‑K notifies investors of a proposed corporate combination that could affect ENDRA’s business structure or strategic relationships. The filing provides notice but does not include merger terms, financial impacts, or required approvals; investors should watch for future SEC filings (e.g., definitive agreements, financial statements, or shareholder notices) that disclose material terms and effects on operations, ownership, or financial results.